Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

    NEXT STORY
    CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH
    PREV STORY
    Helix BioPharma Corp. Provides Update On The Timing Of Filing Of Third Quarter Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma

    author_avatar
    NASDAQ Market News

    Legionella Testing Market is estimated to bring US$398.7 million revenue by 2025 – TMR

    Albany, NY, March 14, 2018 (GLOBE NEWSWIRE) -- According to Transparency Market Research, the ...

    author_avatar
    NASDAQ Market News

    Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., July 16, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the ...

    author_avatar
    NASDAQ Market News